Su Selma, Neman Sophia, Fields Naomi, Luchristt Douglas, Bretschneider C Emi
Division of Urogynecology and Reconstructive Pelvic Surgery, Northwestern Medicine, Chicago, IL, USA.
Medical College of Wisconsin, Milwaukee, WI, USA.
Int Urogynecol J. 2025 Jun 11. doi: 10.1007/s00192-025-06175-1.
Minimally invasive sacrocolpopexy (SCP) with concomitant minimally invasive hysterectomy (MIH) is a frequently employed reconstructive surgical treatment for pelvic organ prolapse; however, the literature is limited regarding how the route of MIH affects postoperative adverse events. This study was aimed at investigating the association of route of MIH at the time of minimally invasive SCP and 30-day postoperative adverse events.
This was a retrospective cohort study using the American College of Surgeons National Surgical Quality Improvement database to compare perioperative adverse events for patients who underwent minimally invasive SCP with MIH for uterovaginal prolapse. MIH included total laparoscopic hysterectomy (TLH), laparoscopic supracervical hysterectomy (SCH), laparoscopy-assisted vaginal hysterectomy (LAVH) and total vaginal hysterectomy (TVH). Perioperative adverse events of the four routes of MIH were compared.
During the study period, 7690 patients were identified. TLH was the most common route of MIH (56%), followed by laparoscopic SCH (39%), TVH (3%), and LAVH (2%). The rate of any 30-day adverse event was 10% and rates were similar between MIH groups. On multivariate logistic regression controlling for confounders, there were no significant differences in rates of postoperative adverse events between MIH groups.
Adverse events following MIH at the time of SCP are not associated with the route of hysterectomy.
微创骶骨阴道固定术(SCP)联合微创子宫切除术(MIH)是治疗盆腔器官脱垂常用的重建性手术;然而,关于MIH的手术路径如何影响术后不良事件的文献有限。本研究旨在调查微创SCP时MIH的手术路径与术后30天不良事件之间的关联。
这是一项回顾性队列研究,使用美国外科医师学会国家外科质量改进数据库,比较因子宫阴道脱垂接受微创SCP联合MIH治疗的患者围手术期不良事件。MIH包括全腹腔镜子宫切除术(TLH)、腹腔镜次全子宫切除术(SCH)、腹腔镜辅助阴道子宫切除术(LAVH)和全阴道子宫切除术(TVH)。比较了MIH四种手术路径的围手术期不良事件。
在研究期间,共纳入7690例患者。TLH是最常见的MIH手术路径(56%),其次是腹腔镜SCH(39%)、TVH(3%)和LAVH(2%)。30天内任何不良事件的发生率为10%,各MIH组之间发生率相似。在控制混杂因素的多因素逻辑回归分析中,各MIH组术后不良事件发生率无显著差异。
SCP时MIH后的不良事件与子宫切除的手术路径无关。